Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Inventory (2016 - 2025)

Cytosorbents' Inventory history spans 15 years, with the latest figure at $5.3 million for Q4 2025.

  • Quarterly results put Inventory at $5.3 million for Q4 2025, up 93.23% from a year ago — trailing twelve months through Dec 2025 was $5.3 million (up 93.23% YoY), and the annual figure for FY2025 was $5.3 million, up 93.23%.
  • Inventory for Q4 2025 was $5.3 million at Cytosorbents, up from $4.0 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $5.4 million in Q1 2022 to a low of $1.7 million in Q1 2023.
  • The 5-year median for Inventory is $3.6 million (2021), against an average of $3.7 million.
  • The sharpest move saw Inventory soared 123.59% in 2021, then plummeted 68.31% in 2023.
  • Year by year, Inventory stood at $4.8 million in 2021, then dropped by 27.37% to $3.5 million in 2022, then dropped by 2.48% to $3.4 million in 2023, then decreased by 19.04% to $2.7 million in 2024, then surged by 93.23% to $5.3 million in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $5.3 million, $4.0 million, and $3.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.